spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  oligonucleotide 

 HSMN NewsFeed - 17 Aug 2026
Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Apr 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Apr 2026
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Mar 2026
ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Aug 2025
Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 30 Apr 2025
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Oct 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2024
Alcyone Therapeutics Announces Appointment of Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer and Head of Research & Development
Biopharmaceuticals Drug Delivery Neurology Personnel
 HSMN NewsFeed - 20 Feb 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jan 2024
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 9 Aug 2023
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Jun 2023
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 29 Nov 2022
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2022
Eleven Therapeutics Announces $22 Million in Seed Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Apr 2022
Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2021
SpliSense Secures $28.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Nov 2020
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
Biopharmaceutical Drug Delivery Personnel
 HSMN NewsFeed - 29 Jul 2020
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 12 Feb 2020
Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2019
Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2019
ReNeuron Provides Business Update and Results Notification
Regenerative Medicine Ophthalmology Neurology
 HSMN NewsFeed - 9 Jan 2019
NapaJen Pharma Closes $12.4 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jan 2019
LifeX Announces Portfolio Company NeuBase Therapeutics To Merge with Ohr Pharmaceutical
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 25 Sep 2018
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2018
Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jan 2018
Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2017
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Jun 2017
Twist Bioscience Raises Additional $27 Million
Biopharmaceuticals Diagnostics Venture Capital
 HSMN NewsFeed - 13 Jun 2017
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2017
Regulus Announces Pipeline Updates and Advancements
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2017
SPINRAZA(R) (nusinersen) Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Apr 2017
RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2017
Twist Bioscience Raises $33 Million
Biopharmaceuticals Diagnostics Venture Capital
 HSMN NewsFeed - 6 Feb 2017
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
Biopharmaceutical Oncology Personnel
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2016
Marina Biotech Announces Merger with IthenaPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Nov 2016
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
Diagnostics Oncology Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2016
Assembly Biosciences Announces Key Additions to Microbiome Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2016
Regulus Secures $30 Million Growth Capital Credit Facility
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Feb 2016
PhaseRx Strengthens Board of Directors and Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2016
Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which is Renamed Kuros Biosciences Ltd.
Devices Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 19 Jan 2016
Twist Bioscience Completes $61 Million Series D Financing And $20 Million Debt Facility
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Nov 2015
miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2015
WAVE Life Sciences Raises $66 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Jul 2015
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2014
Idera Announces Several Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2014
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Oct 2014
Regado Biosciences Appoints Michael A. Metzger CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2014
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2014
ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2014
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2014
Celgene Acquires Late-Stage Product for Crohn’s Disease and Other Gastrointestinal Disorders
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 13 Feb 2014
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
Biopharmaceuticlas Personnel
 HSMN NewsFeed - 4 Feb 2014
Regulus Strengthens Executive Management Team with Addition of David Szekeres as Chief Business Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jan 2014
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Dec 2013
Regado Biosciences Strengthens Executive Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2012
Regado Biosciences, Inc. Secures $51 Million Series E Financing
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 18 Dec 2012
AtheroNova Names New Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2012
Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNA Pipeline into the Clinic
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology
 HSMN NewsFeed - 10 May 2012
RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Nov 2011
Pfizer to Acquire Excaliard Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 May 2011
Regulus Therapeutics Expands Executive Team with Recent Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 May 2011
CoDa Therapeutics Appoints Chief Medical Officer
Biopharmaceuticals Wound Care Personnel
 HSMN NewsFeed - 18 Apr 2011
CoDa Therapeutics Closes $19 Million Series B Financing Round
Biopharmaceuticals Wound Care Venture Capital
 HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2011
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2011
Noxxon Expands Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2010
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2010
AVI BioPharma Announces Key Leadership Appointments to Advance Capabilities in Drug Discovery, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
Tekmira Pharmaceuticals Strengthens Management Team With Addition of Paul Brennan as Senior Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2010
NOXXON Pharma AG raises 33 million in Series D Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 May 2010
NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Apr 2010
Mirina Corporation Closes Series A-1 Financing Led by Versant Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jan 2010
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2009
Regado Biosciences, Inc. Completes $40 Million Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Nov 2009
Arrowhead Subsidiary Calando Pharmaceuticals Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jul 2009
Dicerna Pharmaceuticals Announces Appointment of Industry Veteran David Madden as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2009
Altair Therapeutics Appoints Dr. Joel Martin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2009
Archemix Appoints Ken Bate as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2009
Enzon Announces IND Acceptance for Its Survivin Antagonist
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2009
Archemix Announces Continued Progress with Business Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2009
TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients
Biopharmaceuticals
 HSMN NewsFeed - 24 Sep 2008
ZaBeCor Pharmaceuticals Announces Formation of Biothorpe Pharmaceuticals
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2008
Santaris Pharma Appoints S0ren Tulstrup as New President & CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2008
NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly and Company
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2008
Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2008
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2008
Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2008
Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2008
NOXXON Pharma appoints Dr. Frank Morich as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2007
Meyer Pharmaceuticals Acquires NF-kappaB Decoy Technology for Treatment of Inflammatory Disease
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 6 Nov 2007
Sloning BioTechnology GmbH Raised EUR 4.7m in a First Closing of a Series E Equity Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Sep 2007
NEOPHARM Announces Management Appointment
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2007
Genta Announces Launch of Genasense(R) Named-Patient/Compassionate Use Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2007
Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2007
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 May 2007
AVI BioPharma and Ercole Biotech Announce License and Drug Development Agreement for Duchenne Muscular Dystrophy and Beta Thalassemia
Biopharmaceuticals
 HSMN NewsFeed - 27 Apr 2007
CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Genta Appeals FDA Decision on Genasense(R) in CLL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Mar 2007
Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite(R) and Genasense(R)
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2007
Phase 2 Results of Genasense(R) Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated With Genasense(R) Plus Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense(R) in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Dec 2006
Genta Restructures Operations to Focus on Future Initiatives
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Genta Receives Non-Approvable Notice for Application of Genasense(R) in Patients With Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
Genta Provides Update on Analysis of Phase 3 Trial of Genasense(R) in Older Patients with Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2006
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
Lentigen Appoints Adam L. Sachs to President, Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2006
Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Sep 2006
INEX Updates Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2006
Shareholders of Inex Pharmaceuticals Approve Spin Out of Tekmira Pharmaceuticals Corporation
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2006
Archemix Corp. Strengthens its Board of Directors Adding Alnylam President and CEO, John Maraganore, Ph.D.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2006
Alnylam Grants Bioneer License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 121

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 121 additional stories matching:
oligonucleotide
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!